Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ---- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 ---- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks --BOST...
Source: pharmiweb.com